Upload
dangdang
View
218
Download
0
Embed Size (px)
Citation preview
14/07/2015
1
LUTS 1
BPH / LUTS
Dr Jonny Coxon
MA MD MRCS MRCGP DRCOG
Beaconsfield Medical Practice, Brighton
LUTS 2
“As man draws near the common goal
Can anything be sadder
Than he who, master of his soul
Is servant to his bladder‟
LUTS 3
Plan of attack
• Prevalence including ‘under-reporting’
• Presentation
• What are lower urinary tract symptoms (LUTS)?
• Distinction between storage / voiding etc
LUTS 4
• Initial assessment in primary care
• Medical management
• Who to refer
• What happens in secondary care
Plan of attack
LUTS 5
Prevalence of BPH
LUTS 6
Prevalence
It is abnormal NOT to have benign growth of the prostate with
increasing age
LUTS 7
Prevalence
TZ
PZ
LUTS 8
Prevalence
LUTS 9
Prevalence • 2007 US study: enlarged prostate = 4th most
common diagnosis in men over 50.
• Approximately 1/3 of men over 50 have moderate to severe LUTS
• i.e. ~ 3 million men in UK
14/07/2015
2
LUTS 10
• Huge issue = men reporting symptoms at all
• Some can be rather stoical: “just part of growing old”
Presentation: what do patients say?
LUTS 11
Presentation: what do patients say?
• “I don’t understand it doc, I keep feeling like I need a pee, but hardly any comes out.”
• “My sleeping’s getting terrible.”
• “You know, the public toilets round here are awful”
• “I have to plan my day around toilet breaks”
LUTS 12
• “I might be fine for ages then suddenly, whoosh, I’ve got to go.”
• “I keep having to make excuses in meetings.”
• “I can’t make it round the golf course these days.”
Presentation: what do patients say?
LUTS 13
• “I’m worried about me prostrate”
• “While I’m here doc…”
Presentation: what do patients say?
Lack of
physical
intimacy
Anger or
conflict
Avoidance
or withdrawal
A feeling of
distance or
isolation
Lack of
communication
Re
po
rti
ng
sp
ec
ific
re
lati
on
sh
ip
co
nc
ern
s
Men with mild symptoms (n=216)
Men with moderate-to-severe symptoms (n=203)
Spouses of men with enlarged prostate (n=77)
Roehrborn CG et al. Prostate Cancer Prostatic Dis 2006;9:30–34.
Presentation
LUTS 15
• “I’m worried about me prostrate”
• “While I’m here doc…”
• “I’m here because the wife sent me in.”
Presentation: what do patients say?
LUTS 16
• GPs worry about missing prostate cancer – only 11% confident distinguishing between BPH & PCa
• ~ ½ refer before maximising medical therapy
• GPs seek specialist advice in 1/3 men with LUTS
Presentation: what do we say?
LUTS 17
• Urologists feel ~40% of BPH referrals could be managed in primary care
• ~ 2/3 of urologists agree that interpreting PSA is difficult for GPs
Presentation: what do we say?
LUTS 18
What are LUTS?
• What happened to “prostatism”?
• Or at least “BPH”?
14/07/2015
3
LUTS 19
LUTS =
Lower Urinary Tract Symptoms
BPH =
Benign Prostatic Hyperplasia
BPE =
Benign Prostatic Enlargement
BOO =
Bladder Outlet Obstruction
LUTS 20
What are LUTS?
BPH
BOO
CNS Renal
Cardiac Pituitary
BPE
LUTS 21
LUTS: Storage symptoms
• Urgency +/- Urge Incontinence
• Frequency
• Nocturia
• (Nocturnal enuresis)
(OAB)
LUTS 22
LUTS: Voiding symptoms
• Poor flow
• Intermittency
• Hesitancy
• Straining
• Terminal dribble
LUTS 23
LUTS: Post-micturition
1) Post micturition dribble
2) Incomplete emptying
LUTS 24
LUTS: Assessment
June 2015
LUTS 25
LUTS: Assessment
4 pages of interest:
• Initial assessment
• Referral
• Conservative management
• Drug treatment
LUTS 26
LUTS: Assessment
Consider as minimum 2-part consultation:
• Part 1
– Initial Hx & Ex
– Provide info
– Tests & forms to fill in
• Part 2
– Review & discuss management
LUTS 27
LUTS Assessment: History
• Storage symptoms
• Voiding symptoms
• How much bother from symptoms?
• What is the patient’s worry?
14/07/2015
4
LUTS 28
LUTS Assessment: History
• Other elements of PMH, e.g.
– Diabetes
– Heart failure
– Kidney failure
– Liver failure
– OSA
– Oedema, chronic venous stasis
– Neurological conditions
LUTS 29
LUTS Assessment: History
• Medications, e.g.:
– α-blockers
– Diuretics
– Ca channel blockers
– SSRIs
– Bronchodilators (anti-cholinergics)
– Antihistamines
LUTS 30
LUTS Assessment: History
• Medications, e.g.:
– Lithium
– Benzodiazepines
– NSAIDs
– Pioglitazone
– Gabapentin
– Pregabalin
LUTS 31
LUTS Assessment: Examination
• Abdomen
• External genitalia
• PR / DRE
LUTS 32
LUTS Assessment: Examination
PR / DRE:
• Is it smooth?
• Is it big?
LUTS 33
LUTS Assessment: Examination
LUTS 34
LUTS Assessment: Examination
LUTS 35
LUTS Assessment: Investigations
• Urine dipstick test
• Bloods:
– “Offer a serum creatinine test only if you suspect renal impairment”
– PSA?
LUTS 36
• Offer men information, advice and time to decide if they wish to have PSA testing if:
– LUTS are suggestive of bladder outlet obstruction secondary to BPE or
– their prostate feels abnormal on DRE or
– they are concerned about prostate cancer
LUTS Assessment: PSA?
14/07/2015
5
LUTS 37
LUTS Assessment: Investigations
• “Ask men with bothersome LUTS to complete a urinary frequency volume chart.”
• “Offer men considering treatment an assessment of baseline symptoms with a validated symptom score (e.g. IPSS).”
LUTS 38 LUTS 39
LUTS Assessment: Investigations
• What’s normal?
• Void: ~250ml
• Fluid in: ~1.5-2L / 24 hrs
• Urine out: ~1.5-2L / 24 hrs
– 30ml/kg / 24hrs
• Frequency: > 8 voids/ 24hrs
• Nocturia: as > 1 void at night
• (Nocturnal polyuria: >⅓ volume at night)
LUTS 40
LUTS Assessment: Investigations
• Small volume voids with variation in voided volume – characteristic of OAB
• Small volume voids without significant variation in voided volume:
LUTS 41
LUTS 42
LUTS 43
• Ask re ED
• Measure BP
• Might add to bloods:
– Lipids
– Glucose
LUTS Assessment: Not NICE LUTS & Erectile Dysfunction
Inc
ide
nc
e , %
2
12
2
25
5
45
17
53
7
33
6
43
12
53
19
64
16
41
20
50
31
52
44 45
0
10
20
30
40
50
60
70 No, I cannot get an erection
Net reduction in stiffness
Rosen et al. Eur Urol 2003;44(6):637-49.
LUTS Severity
Age 50 – 59 years
LUTS Severity
Age 60 – 69 years
LUTS Severity
Age 70 – 79 years
LUTS 45
• Interest in sex declines with worsening LUTS
• Many studies shown association of LUTS with ED
• Prostate disease 2nd only to DM as ED risk factor:
– more than PVD, hyperlipidaemia, HT, depression, IHD.
LUTS & ED
14/07/2015
6
LUTS 46
• Treatment itself can worsen or even improve sexual function
• Unclear how much association is physiological, or related to sleep disturbance/anxiety
LUTS & ED
LUTS 47
LUTS & Metabolic Syndrome
Gacci et al, Eur Urol 2011; 60: 809-825
LUTS 48
Link with Metabolic Syndrome
N=409, men presenting with moderate/severe LUTS Lee et al BJUI 2012; 110:540-5
LUTS 49
Link with Metabolic Syndrome
N=409, men presenting with moderate/severe LUTS Lee et al BJUI 2012; 110:540-5
LUTS 50
LUTS & Metabolic Syndrome
Kellogg Parsons J et al Eur Urol 2011
LUTS 51
LUTS & Metabolic Syndrome
St Sauver JL et al BJU Int 2010
LUTS 52
LUTS & Metabolic Syndrome
LUTS 53
LUTS & Metabolic Syndrome
• Primary Care = ideal setting for holistic management of male LUTS
• The prostate as the “gateway to men’s health”
LUTS 54
LUTS Management
Uncomplicated LUTS Complicated LUTS
• Gradual onset
• Impalpable bladder
• Normal external genitalia
• Benign feeling prostate
• Normal PSA
• No infection / haematuria
• Raised PSA / Abnormal DRE
• Pelvic / Urogenital pain
• UTI / Dysuria
• Palpable bladder
• Incontinence
• Haematuria
• Severe symptoms
• Bladder stones!
14/07/2015
7
LUTS 55
LUTS Management
• If LUTS not bothersome or complicated, reassure
Cancer worry:
• Actually for majority of cases, NO strong link between LUTS & onset of prostate cancer
LUTS 56
LUTS Management
• Think possible causes (PMH/Meds)
• Offer:
– advice on lifestyle interventions (e.g. fluid intake, caffeine, time of diuretics)
– information on the condition
LUTS 57
LUTS 58
LUTS Management
• For men with mild-moderate bothersome LUTS, discuss:
• Active surveillance:
– reassurance & lifestyle advice without immediate treatment, or
• Active intervention:
– conservative management
– drug treatment
– surgery
LUTS 59
LUTS Management - Conservative
• If you suspect OAB, offer:
– supervised bladder training
– lifestyle advice, fluid intake
– if needed, containment products.
LUTS 60
LUTS Management - Conservative
• If you suspect OAB, offer:
– supervised bladder training
– lifestyle advice, fluid intake
– if needed, containment products.
• Do not offer penile clamps
LUTS 61
LUTS Management - Conservative
• For men with storage LUTS (particularly urge incontinence):
– Offer temporary containment products (e.g. pads or collecting devices)
– Achieve social continence until diagnosis & management plan discussed
LUTS 62
LUTS Management - Conservative
• Explain to men with post-micturition dribble how to perform urethral milking:
LUTS 63
LUTS Management – Drug Rx
• Often only if bothersome LUTS, & conservative management unsuccessful or not appropriate.
• Do not offer homeopathy, phytotherapy or acupuncture.
14/07/2015
8
LUTS 64
LUTS Management – Drug Rx
• Overactive bladder:
–Offer an anticholinergic
LUTS 65
LUTS Management – Drug Rx
• Overactive bladder:
–mirabegron (Betmiga), 50mg od
–β3-adrenoceptor agonist
–Newly licensed 2013 for OAB
• NICE: only if anticholinergic is ineffective, contraindicated or not tolerated
LUTS 66
LUTS Management – Drug Rx 1. Moderate to severe LUTS (not OAB predominant):
–Offer an α-blocker
2. LUTS with PSA >1.4, prostate >30g:
- high risk of progression:
–Offer a 5-α reductase inhibitor (5-ARI)
1 and 2:
–Offer combination treatment
LUTS 67
• Progression =
– Worsening symptoms
– Acute retention
– BPH-related surgery
Risk factors:
– Age over 70
– Moderate to severe symptoms that are bothersome
– PSA > 1.4 ng/ml, Prostate volume >30ml
LUTS Management – Drug Rx
LUTS 68
Adapted from Marberger MJ et al Eur Urol 2000;38:563-568.
Risk of AUR by Baseline Serum PSA in Untreated Men (Placebo Group)
% o
f m
en
wit
h A
UR
(2
ye
ars
)
Serum PSA level <1.4 ng/ml
(n=705)
Serum PSA level ≥1.4 ng/ml
(n=1394)
9-fold increase in risk (p<0.001)
0.4
3.9
5
4
3
2
1
0
LUTS 69
LUTS Management: α-blockers
• Reduce tone of bladder neck / prostate
• Ideal first line in primary care for ‘mixed LUTS’
• Rapid onset 4-6 weeks
• No effect on PSA level or prostate size
LUTS 70
LUTS Management: α-blockers
• BUT do not prevent progression
• S/E include: dizzy, faint, weak, bowel effects, headache, ejaculatory dysfunction …
LUTS 71
LUTS Management: 5-ARIs
• Inhibit conversion of T to DHT
• ↓prostate volume
• Most effective in larger prostates
LUTS 72
LUTS Management: 5-ARIs
• Beneficial effects start at 6-9 months, fully develop over years
• ↓symptoms & ↓rate of AUR / surgery
• S/E include: fatigue, ED, ↓ libido, gynaecomastia
14/07/2015
9
–60
–50
–40
–30
–20
–10
0
10
20
0 6 12 18 24 30 36 42 48
Treatment month
Me
an
ch
an
ge
in
PS
A (
%)
Double-blind1 Open phase2
placebo
dutasteride
1. Adapted from Roehrborn CG et al. Urology 2002; 60: 434-441.
2. Adapted from Debruyne F et al. Eur Urol 2004; 46: 488-495.
5.5 2.2
10.7 6.8
15.0
2.8
–50.5
–35.7
–48.6 –43.5
–9.2
-52.9
–48.4
–57.2
5-ARIs reduce PSA level
LUTS 74
LUTS Management: 5-ARIs & PSA
• Any confirmed increase from lowest PSA level may signal non-compliance to therapy, or prostate cancer (particularly high-grade)
– should be carefully evaluated
• Can still use PSA to help risk assessment of PCa, after a new baseline established
LUTS 75
LUTS Management: Combination
LUTS 76
LUTS Management: Combination
• Studies show combination Rx:
–Most effective for controlling symptoms
–Most effective for reducing progression
• e.g. At 4 years, combination vs tamsulosin alone reduced risk of AUR / surgery by 70%
• 7.7% actual risk reduction (NNT=13)
Roehrborn CG et al. J Urol 2008;179:616–21;
Siami P et al. Contemp Clin Trials 2007;28:770–9
McConnell JD et al. NEJM 2003;349:2387–98
LUTS 77 LUTS 78
LUTS 79 LUTS 80
LUTS Management – Drug Rx
2012:
Cialis (tadalafil) 5 mg od: Licensed for treating the “signs & symptoms of BPH”
SLS restrictions amended, so can prescribe for condition other than ED
LUTS 81
LUTS Management – Drug Rx
Tadalafil for LUTS:
• IPSS scores do improve
• May be more effective combined with α-blocker (caution)
• NICE 2015: Do not offer solely for LUTS, unless part of a trial
14/07/2015
10
LUTS Management – Drug Rx
Oelke et al. Eur Urol 2012;61: 917 - 925
* Please note that tamsulosin is an active control. This study was powered for direct comparisons between tadalafil and placebo and between tamsulosin and placebo.
IPSS: Tadalafil vs placebo & Tamsulosin vs placebo
Add muscarinic receptor antagonist
+ continue with Edu/Lifestyle
Edu/Lifestyle with or without
5-ARI ± α1-blocker/
PDE5-I
Male LUTS EAU Guidelines 2015
(without indications for surgery)
Watchful waiting
with or without Edu/Lifestyle
Edu/Lifestyle with or without Anti cholinergic
Edu/Lifestyle with or without Vasopressin
Analogue
Bothersome symptoms?
Storage symptoms predominant?
Edu/Lifestyle with or without
α1-blocker/PDE5-I
- + Nocturnal polyuria
predominant?
Prostate volume >40 ml?
Long-term treatment?
Residual storage symptoms
-
-
-
-
+
+
+
+
Gratzke C et al. Eur Urol 2015;67:1099-1109
LUTS Management – Drug Rx
LUTS 86
LUTS Management – Drug Rx
Back to NICE:
• Consider adding an anticholinergic if storage symptoms after α–blocker alone for LUTS
• LOW risk of retention
LUTS 87
LUTS Management – Drug Rx Back to NICE:
• Nocturnal polyuria (>1/3 urine at night)
– Consider late-afternoon loop diuretic
– Consider oral desmopressin, if other medical causes have been excluded
LUTS 88
LUTS: Referral
• Bothersome LUTS not responded to conservative & drug management
• LUTS complicated by:
– recurrent or persistent UTI
– retention (acute / chronic)
– renal impairment thought due to LUT dysfunction
– stress urinary incontinence
LUTS 89
LUTS: Secondary Care
• Flow-rate
• Post-void residual
LUTS 90
LUTS: Secondary Care
• Flow-rate
• Post-void residual
• Possibly:
– Cystoscopy
– Upper tract imaging
14/07/2015
11
LUTS 91
LUTS: Secondary Care
• Flow-rate
• Post-void residual
• Possibly:
– Cystoscopy
– Upper tract imaging
– Urodynamics (if considering surgery)
LUTS 92
LUTS: Surgery Voiding:
• TURP
• TUVP
• HoLEP (laser)
• TUIP (often smaller prostates, younger men)
• ‘Urolift’ for some
LUTS 93
LUTS: Surgery
Storage:
• Botox injections
• Sacral / tibial nerve stimulation
• Cystoplasty
LUTS 94
LUTS: Surgery
Stress incontinence:
• Implantation of an artificial sphincter
LUTS 95
LUTS: SUMMARY
• Common, under-reported
• Ask: what is bothering the patient?
• Strong link with ED / Metabolic Syndrome
• Holistic assessment
• Think: balls
LUTS 96
LUTS: SUMMARY
• Lifestyle intervention especially fluid intake
• Medical therapy according to symptoms
• Find & treat nocturnal polyuria
• Remember: a progressive condition
• Refer if not responding / atypical / complicated